ClinicalTrials.gg
RecruitingNCT07734649Updated Oct 14, 2026

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

A Phase 1/2 interventional study of RSV+HMPV vaccine and Control Vaccine 3 in Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization and Healthy Volunteers, sponsored by Sanofi. Recruiting at 50 sites in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Sanofi · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 14, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
2,400
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years of age and older. The aim of the study is to evaluate the immunogenicity and safety of an RSV+HMPV vaccine candidate for the prevention of RSV and HMPV disease among adults 60 years of age and older. While there are 3 FDA approved/licensed RSV vaccines currently available to the public, no vaccine is available for the prevention of HMPV in older adults. This study is intended to provide data in support of further clinical development of the RSV+HMPV vaccine candidate.

The study will consist of 4 cohorts and 11 vaccine groups (RSV+HMPV [6 dose levels], placebo and 4 control groups).

The duration of the study will be approximately 12 months for each participant.

02

Conditions studied

  • Respiratory Syncytial Virus Immunization
  • Human Metapneumovirus Immunization
  • Healthy Volunteers

Keywords

  • RSV
  • HMPV
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 60 years or older on the day of inclusion
  • Non- (ie, for at least 1 year or surgically sterile)

Exclusion criteria

Exclusion Criteria:

  • History of laboratory-confirmed RSV and/or laboratory-confirmed HMPV infection affecting the participant and/or the participant's household in the previous 12 months
  • Previous history of myocarditis, pericarditis, and/or myopericarditis
  • Screening (ECG) that is consistent with possible myocarditis, pericarditis, and/or myopericarditis or, in the opinion of the investigator, demonstrates abnormalities that may affect participant safety or study results
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Previous history of Guillain-Barré Syndrome
  • Any vaccine given 4 weeks before or 4 weeks after study intervention
  • Previous vaccination against RSV and/or HMPV with an or marketed vaccine
  • Receipt of any mRNA vaccine/product in the 2 months preceding study intervention administration
  • Has received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months
  • Any screening laboratory parameter with laboratory abnormality > Grade 1 or deemed clinically significant by the investigator; if deemed appropriate, investigator may repeat these assessments

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,400 participants (estimated)

Study arms

  • Experimental
    Group 1: RSV + HMPV Vaccine-Dose 1

    Participants will receive RSV + HMPV vaccine corresponding to Dose 1 with a predefined antigen ratio

    Biological: RSV+HMPV vaccine

  • Experimental
    Group 2: RSV + HMPV Vaccine-Dose 2

    Participants will receive RSV + HMPV vaccine corresponding to Dose 2 with a predefined antigen ratio

    Biological: RSV+HMPV vaccine

  • Experimental
    Group 3: RSV + HMPV Vaccine-Dose 3

    Participants will receive RSV + HMPV vaccine corresponding to Dose 3 with a predefined antigen ratio

    Biological: RSV+HMPV vaccine

  • Experimental
    Group 4: RSV + HMPV Vaccine-Dose 4

    Participants will receive RSV + HMPV vaccine corresponding to Dose 4 with a predefined antigen ratio

    Biological: RSV+HMPV vaccine

  • Experimental
    Group 5: RSV + HMPV Vaccine-Dose 5

    Participants will receive RSV + HMPV vaccine corresponding to Dose 5 with a predefined antigen ratio

    Biological: RSV+HMPV vaccine

  • Experimental
    Group 6: RSV + HMPV Vaccine-Dose 6

    Participants will receive RSV + HMPV vaccine corresponding to Dose 6 with a predefined antigen ratio

    Biological: RSV+HMPV vaccine

  • Active comparator
    Group 7: Control Vaccine 1

    Participants will receive control vaccine 1

    Biological: Control Vaccine 1

  • Placebo comparator
    Group 8: Placebo

    Participants will receive Placebo

    Other: Placebo

  • Other
    Group 9: Control Vaccine 2

    Participants will receive control vaccine 2 at a predefined dose and antigen ratio

    Biological: Control Vaccine 2

  • Other
    Group 10: Control Vaccine 3

    Participants will receive control vaccine 3 at a predefined dose

    Biological: Control Vaccine 3

  • Other
    Group 11: Control Vaccine 4

    Participants will receive control vaccine 4 at a predefined dose

    Biological: Control Vaccine 4

Interventions

  • BiologicalRSV+HMPV vaccine

    RSV + HMPV Candidate Vaccine

  • BiologicalControl Vaccine 3

    Control Vaccine 3

  • BiologicalControl Vaccine 4

    Control Vaccine 4

  • BiologicalControl Vaccine 2

    Control Vaccine 2

  • OtherPlacebo

    Placebo

  • BiologicalControl Vaccine 1

    Control Vaccine 1

06

What researchers measure

Primary outcomes

  1. RSV A serum nAb (neutralizing antibodies) titers

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At Day 1 and Day 29

  2. RSV B serum nAb titers

    nAb titers expressed as GMTs

    Time frame: At Day 1 and Day 29

  3. HMPV A serum nAb titers

    nAb titers expressed as GMTs

    Time frame: At Day 1 and Day 29

  4. HMPV B serum nAb titers

    nAb titers expressed as GMTs

    Time frame: At Day 1 and Day 29

  5. Unsolicited systemic Adverse Events (AEs) that occur within 30 minutes after vaccination

    Number of participants reporting immediate unsolicited systemic AEs

    Time frame: Within 30 minutes after vaccination

  6. Presence of solicited injection site and systemic reactions

    Number of participants reporting: * injection site reactions: pain, erythema and swelling * systemic reactions: fever, headache, fatigue and myalgia

    Time frame: For 8 days, including the day of vaccination

  7. Presence of Unsolicited AEs

    Number of participants reporting unsolicited AEs

    Time frame: For 28 days, including day of vaccination

  8. Presence of medically attended AEs (MAAEs)

    Number of participants reporting MAAEs

    Time frame: Within 6 months after vaccination

  9. Presence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

    Number of participants reporting SAEs and AESIs

    Time frame: Throughout the study (approximately 12 months)

  10. Presence of out-of-range biological test results

    Number of participants with biological safety assessment values out of normal range (including shift from baseline values)

    Time frame: At Day 09

Secondary outcomes

  1. RSV A serum nAb titers at 3, 6, 9, and 12 months post-vaccination

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: 3, 6, 9, and 12-months post-vaccination

  2. RSV B serum nAb titers at 3, 6, 9, and 12 months post-vaccination

    nAb titers expressed as GMTs

    Time frame: 3, 6, 9, and 12 months post-vaccination

  3. HMPV A serum nAb titers at 3, 6, 9, and 12 months post-vaccination

    nAb titers expressed as GMTs

    Time frame: 3, 6, 9, and 12 months post-vaccination

  4. HMPV B serum nAb titers at 3, 6, 9, and 12 months post-vaccination

    nAb titers expressed as GMTs

    Time frame: 3, 6, 9, and 12 months post-vaccination

  5. Serum RSV preF immunoglobulin G (IgG) Ab concentrations at pre-vaccination (Day 01), and at 28 days (Day 29), 3, 6, 9, and 12 months post-vaccination

    Ab concentration expressed as geometric mean concentrations (GMCs)

    Time frame: pre-vaccination (Day 01), and at 28 days (Day 29), 3, 6, 9, and 12 months post-vaccination

  6. Serum HMPV preF immunoglobulin G (IgG) Ab concentrations at pre-vaccination (Day 01), and at 28 days (Day 29), 3, 6, 9, and 12 months post-vaccination

    Ab concentration expressed as GMCs

    Time frame: pre-vaccination (Day 01), and at 28 days (Day 29), 3, 6, 9, and 12 months post-vaccination

  7. Ratio of RSV A and RSV B serum nAb titer fold-rise over anti-preF IgG Ab concentration fold-rise at Day 29, 3, 6, 9, and 12 months post-vaccination, from pre vaccination (Day 01)

    Time frame: Day 29, 3, 6, 9, and 12 months post-vaccination, from pre-vaccination (Day 01)

  8. Ratio of HMPV A and HMPV B serum nAb titer fold-rise over anti-preF IgG Ab concentration fold-rise at Day 29, 3, 6, 9, and 12 months post-vaccination, from pre vaccination (Day 01)

    Time frame: Day 29, 3, 6, 9, and 12 months post-vaccination, from pre-vaccination (Day 01)

07

Study locations

50 of 50 sites recruiting
  • Hawthorne Health - Gadsden- Site Number : 8400025
    Gadsden, Alabama 35901, United States
    Recruiting
  • Accel Research Sites Network - Birmingham- Site Number : 8400065
    Vestavia Hills, Alabama 35216, United States
    Recruiting
  • Marvel Clinical Research- Site Number : 8400006
    Huntington Beach, California 92647, United States
    Recruiting
  • Velocity Clinical Research - San Diego- Site Number : 8400019
    La Mesa, California 91942, United States
    Recruiting
  • Long Beach Research Institute- Site Number : 8400005
    Long Beach, California 90805, United States
    Recruiting
  • Acclaim Clinical Research- Site Number : 8400033
    San Diego, California 92120, United States
    Recruiting
  • Velocity Clinical Research - Washington DC- Site Number : 8400021
    Washington D.C., District of Columbia 20016, United States
    Recruiting
  • Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400064
    DeLand, Florida 32720, United States
    Recruiting
  • Velocity Clinical Research - New Smyrna Beach- Site Number : 8400017
    Edgewater, Florida 32132, United States
    Recruiting
  • Accel Research Sites - Lakeland Clinical Research Unit- Site Number : 8400073
    Lakeland, Florida 33803, United States
    Recruiting
  • Accel Research Sites - St. Petersburg - Largo- Site Number : 8400067
    Largo, Florida 33777, United States
    Recruiting
  • Accel Research Sites - Maitland Clinical Research Unit- Site Number : 8400074
    Maitland, Florida 32751, United States
    Recruiting
  • Alcanza - Innovation Medical Research Center - Palmetto- Site Number : 8400069
    Palmetto Bay, Florida 33157, United States
    Recruiting
  • Accel Research Sites - NeuroStudies- Site Number : 8400063
    Decatur, Georgia 30030, United States
    Recruiting
  • North Georgia Clinical Research- Site Number : 8400078
    Woodstock, Georgia 30189, United States
    Recruiting
  • DM Clinical Research - Chicago- Site Number : 8400050
    Melrose Park, Illinois 60160, United States
    Recruiting
  • Enspire Clinical Research- Site Number : 8400077
    Peoria, Illinois 61614, United States
    Recruiting
  • DM Clinical Research - Indianapolis- Site Number : 8400082
    Indianapolis, Indiana 46254, United States
    Recruiting
  • Velocity Clinical Research - New Orleans- Site Number : 8400022
    New Orleans, Louisiana 70119, United States
    Recruiting
  • Boston Clinical Trials- Site Number : 8400070
    Boston, Massachusetts 02131, United States
    Recruiting
  • DM Clinical Research - Brookline- Site Number : 8400055
    Brookline, Massachusetts 02446, United States
    Recruiting
  • ActivMed Practices & Research - Methuen- Site Number : 8400066
    Methuen, Massachusetts 01844, United States
    Recruiting
  • QUEST Research Institute- Site Number : 8400068
    Farmington Hills, Michigan 48334, United States
    Recruiting
  • DM Clinical Research - Detroit- Site Number : 8400049
    Southfield, Michigan 48076, United States
    Recruiting
  • Velocity Clinical Research - Lincoln - Valley Road- Site Number : 8400016
    Lincoln, Nebraska 68510, United States
    Recruiting
  • Velocity Clinical Research - Omaha- Site Number : 8400012
    Omaha, Nebraska 68134, United States
    Recruiting
  • Alliance Clinical - Las Vegas- Site Number : 8400034
    Las Vegas, Nevada 89109, United States
    Recruiting
  • DM Clinical Research - New Jersey- Site Number : 8400044
    Jersey City, New Jersey 07306, United States
    Recruiting
  • Hawthorne - Bienstar Lindenwold- Site Number : 8400027
    Lindenwold, New Jersey 08021, United States
    Recruiting
  • DM Clinical Research - Albuquerque- Site Number : 8400051
    Albuquerque, New Mexico 87106, United States
    Recruiting
  • Hawthorne Health - Staten Island- Site Number : 8400026
    Staten Island, New York 10309, United States
    Recruiting
  • Velocity Clinical Research - Cleveland- Site Number : 8400024
    Beachwood, Ohio 44122, United States
    Recruiting
  • Velocity Clinical Research - Springdale- Site Number : 8400014
    Cincinnati, Ohio 45246, United States
    Recruiting
  • DM Clinical Research - Philadelphia- Site Number : 8400046
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Velocity Clinical Research - Providence- Site Number : 8400018
    East Greenwich, Rhode Island 02818, United States
    Recruiting
  • Coastal Carolina Research Center - North Charleston- Site Number : 8400061
    North Charleston, South Carolina 29405, United States
    Recruiting
  • Velocity Clinical Research - Austin- Site Number : 8400013
    Austin, Texas 78759, United States
    Recruiting
  • Zenos Clinical Research- Site Number : 8400032
    Dallas, Texas 75230, United States
    Recruiting
  • DM Clinical Research - CyFair Clinical Research Center- Site Number : 8400058
    Houston, Texas 77065, United States
    Recruiting
  • Texas Center for Drug Development - Houston- Site Number : 8400043
    Houston, Texas 77081, United States
    Recruiting
  • DM Clinical Research - Dallas- Site Number : 8400059
    Irving, Texas 75061, United States
    Recruiting
  • DM Clinical Research - San Antonio - North San Saba- Site Number : 8400056
    San Antonio, Texas 78207, United States
    Recruiting
  • DM Clinical Research - San Antonio - North San Saba- Site Number : 8400057
    San Antonio, Texas 78207, United States
    Recruiting
  • DM Clinical Research - Sugar Land- Site Number : 8400048
    Sugar Land, Texas 77478, United States
    Recruiting
  • Olympus Clinical Research - Sugar Land- Site Number : 8400071
    Sugar Land, Texas 77478, United States
    Recruiting
  • DM Clinical Research - Tomball- Site Number : 8400045
    Tomball, Texas 77375, United States
    Recruiting
  • DM Clinical Research - Tomball- Site Number : 8400081
    Tomball, Texas 77375, United States
    Recruiting
  • Charlottesville Medical Research- Site Number : 8400062
    Charlottesville, Virginia 22911, United States
    Recruiting
  • Velocity Clinical Research - Hampton- Site Number : 8400015
    Hampton, Virginia 23666, United States
    Recruiting
  • Dm Clinical - Seattle- Site Number : 8400047
    Seattle, Washington 98122, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for May 2028, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 29, 2026
StartActual
Jul 22, 2026
Primary completionEst.
May 3, 2028
CompletionEst.
May 3, 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPresence of Serious Adverse Events (SAEs), fatal SAEs and Adverse Events of Special Interest (AESIs)Time frame: Throughout the study (approximately 12 months)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPresence of Serious Adverse Events (SAEs), fatal SAEs and Adverse Events of Special Interest (AESIs)Time frame: Throughout the study (approximately 12 months)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07734649
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Jul 22, 2026
Primary completion
May 3, 2028 (estimated)
Completion
May 3, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion